Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
Hartmut Döhner(University Hospital Ulm), Andrew H. Wei(The Royal Melbourne Hospital), Frederick R. Appelbaum(University of Washington), Charles Craddock(Queen Elizabeth Hospital Birmingham), Courtney D. DiNardo(The University of Texas MD Anderson Cancer Center), Hervé Dombret(Université Paris Cité), Benjamin L. Ebert(Dana-Farber Cancer Institute), Pierre Fenaux(Assistance Publique – Hôpitaux de Paris), Lucy A. Godley(University of Chicago), Robert P. Hasserjian(Massachusetts General Hospital), Richard A. Larson(University of Chicago), Ross L. Levine(Memorial Sloan Kettering Cancer Center), Yasushi Miyazaki(Nagasaki University), Dietger Niederwieser(Leipzig University), Gert J. Ossenkoppele(Amsterdam UMC Location Vrije Universiteit Amsterdam), Christoph Röllig(University Hospital Carl Gustav Carus), Jorge Sierra(Hospital de Sant Pau), Eytan M. Stein(Memorial Sloan Kettering Cancer Center), Martin S. Tallman(Memorial Sloan Kettering Cancer Center), Hwei‐Fang Tien(National Taiwan University Hospital), Jianxiang Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Agnieszka Wierzbowska(Medical University of Lodz), Bob Löwenberg(Erasmus MC)
Cited by 2,947Open Access
Abstract
The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update of the disease classification, technological progress in genomic diagnostics and assessment of measurable residual disease, and the successful development of new therapeutic agents, such as FLT3, IDH1, IDH2, and BCL2 inhibitors. These advances have prompted this update that includes a revised ELN genetic risk classification, revised response criteria, and treatment recommendations.
Related Papers
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network|New England Journal of Medicine|2013|5.1k
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
Anand Padmanabhan, Laura Connelly‐Smith, Nicole A. Aqui et al.|Journal of Clinical Apheresis|2019|2.2k